Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.67 |
| ▸ | JAK3 | P52333 | 7/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.67 |
| ▸ | IGF1R | P08069 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.67 |
| ▸ | AURKA | O14965 | 2/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | PAK4 | O96013 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | FER | P16591 | 1/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.67 |
| ▸ | JAK1 | P23458 | 1/20 | 0.67 |
| ▸ | TYK2 | P29597 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.67 |
| ▸ | STAT3 | P40763 | 1/20 | 0.67 |
| ▸ | STAT5A | P42229 | 1/20 | 0.67 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.67 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338537 | 0.88 | IGF1R (0.67) | JAK2JAK3NTRK1FGFR1IGF1R | |
| SCHEMBL18853845 | 0.84 | JAK2 (0.84) | JAK2JAK3NTRK1FGFR1IGF1R | |
| Azd-1480 SCHEMBL3345019 | 0.80 | JAK2 (1.00) | JAK2JAK3NTRK1FGFR1AURKA | |
| Azd-1480 SCHEMBL29523565 | 0.80 | JAK2 (1.00) | JAK2JAK3NTRK1FGFR1AURKA | |
| Azd-1480 SCHEMBL220400 | 0.80 | JAK2 (1.00) | JAK2JAK3NTRK1FGFR1AURKA | |
| SCHEMBL2121130 | 0.80 | IGF1R (1.00) | JAK2JAK3NTRK1FGFR1IGF1R | |
| Azd-1480 SCHEMBL219103 | 0.80 | JAK2 (1.00) | JAK2JAK3NTRK1FGFR1AURKA | |
| SCHEMBL4076083 | 0.79 | NTRK1 (1.00) | JAK2JAK3NTRK1FGFR1AURKA | |
| SCHEMBL3335945 | 0.78 | NTRK1 (0.72) | JAK2JAK3NTRK1FGFR1IGF1R | |
| SCHEMBL3033142 | 0.78 | NTRK1 (0.78) | JAK2JAK3NTRK1FGFR1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | claimed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | claimed |
| JP-2007511589-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | claimed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1877057-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2008-01-16 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006115452-A1 | USE OF PYRAZOLYL-PYRIMIDINE DERIVATIVES IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | WO | disclosed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| CN-1617858-A | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | JAK2 179/4885JAK3 215/4885NTRK1 7/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | JAK2 144/4885JAK3 166/4885NTRK1 15/4885 |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | JAK2 1971/4885JAK3 1598/4885NTRK1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.